Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor

  • Authors:
    • Rikio Yoshimura
    • Kenichiro Inoue
    • Yutaka Kawahito
    • Makoto Mitsuhashi
    • Kenji Tsuchida
    • Masahide Matsuyama
    • Hajime Sano
    • Tatsuya Nakatani
  • View Affiliations

  • Published online on: January 1, 2004     https://doi.org/10.3892/ijmm.13.1.41
  • Pages: 41-46
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The metabolism of arachidonic acid (AA) by either the cyclooxygenase (COX) or lipoxygenase (LOX) pathway generates eicosanoids, has been implicated in the pathogenesis of a variety of human diseases, including cancer, and may play important roles in tumor promotion, progression, and metastasis. The involvement of 12-LOX expression and function in tumor growth and metastasis has been reported in both murine and human tumor cell lines. The expression of 12-LOX in human renal cell carcinoma (RCC), normal kidney (NK) tissues and 3 kinds of RCC cell lines (Caki-1, A498, RC-1), and its effects on cell proliferation in 3 RCC cell lines were examined. Expression of 12-LOX protein was detected by immunohistochemistry and 12-LOX mRNA in RCC cell lines was detected by nested RT-PCR. Effects of 12-LOX inhibitor on RCC cell growth was examined by MTT assay, and to determine whether or not 12-LOX inhibitors induce apoptosis, we used Hoechst staining. While 12-LOX expression was detected slightly in NK tissues, a marked expression of 12-LOX was detected in RCC tissues. All human RCC cell lines expressed 12-LOX mRNA. The 12-LOX inhibitor baicalein caused marked inhibition of all three kinds of RCC cells in a concentration- and time-dependent manner. Cells treated with 12-LOX inhibitor showed chromatin condensation, cellular shrinkage, small membrane-bound bodies (apoptotic bodies), and cytoplasmic condensation. These results suggest 12-LOX may play a role in the progression of RCC in human tissue, and its inhibitors may become anticancer agents in human RCC.

Related Articles

Journal Cover

January 2004
Volume 13 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yoshimura R, Inoue K, Kawahito Y, Mitsuhashi M, Tsuchida K, Matsuyama M, Sano H and Nakatani T: Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor. Int J Mol Med 13: 41-46, 2004.
APA
Yoshimura, R., Inoue, K., Kawahito, Y., Mitsuhashi, M., Tsuchida, K., Matsuyama, M. ... Nakatani, T. (2004). Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor. International Journal of Molecular Medicine, 13, 41-46. https://doi.org/10.3892/ijmm.13.1.41
MLA
Yoshimura, R., Inoue, K., Kawahito, Y., Mitsuhashi, M., Tsuchida, K., Matsuyama, M., Sano, H., Nakatani, T."Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor". International Journal of Molecular Medicine 13.1 (2004): 41-46.
Chicago
Yoshimura, R., Inoue, K., Kawahito, Y., Mitsuhashi, M., Tsuchida, K., Matsuyama, M., Sano, H., Nakatani, T."Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor". International Journal of Molecular Medicine 13, no. 1 (2004): 41-46. https://doi.org/10.3892/ijmm.13.1.41